Obesity - Pipeline Review, H1 2018
Obesity - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H1 2018, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 18, 28, 1, 120, 32 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 10 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Abeome Corp
Adocia SAS
Aegis Therapeutics LLC
Amgen Inc
Antag Therapeutics ApS
Aoxing Pharmaceutical Company Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Athersys Inc
Auris Medical Holding AG
Bial - Portela & Ca SA
Biophytis SA
BioRestorative Therapies Inc
Biozeus
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3J Therapeutics Inc
Callitas Therapeutics Inc
Carmot Therapeutics Inc
Celon Pharma SA
Chong Kun Dang Pharmaceutical Corp
CohBar Inc
CoMentis Inc
Corcept Therapeutics Inc
Daiichi Sankyo Co Ltd
DiscoveryBiomed Inc
Eisai Co Ltd
Eli Lilly and Co
Eternygen GmbH
Evotec AG
FibroGen Inc
Genmedica Therapeutics SL
Gila Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
Intarcia Therapeutics Inc
Ionis Pharmaceuticals Inc
Johnson & Johnson
Juno Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Leading BioSciences Inc
Magnus Life Ltd
MedImmune LLC
Merck & Co Inc
Naia Ltd
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
NIBEC
Nordic Bioscience A/S
Novartis AG
Novo Nordisk AS
ObeTherapy Biotechnology
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Palatin Technologies Inc
Peptron Inc
Pfizer Inc
PharmaIN Corp
Poxel SA
ProMetic Life Sciences Inc
Regeneron Pharmaceuticals Inc
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc
Saniona AB
Sanofi
Seres Therapeutics Inc
Shionogi & Co Ltd
Sinil Pharmaceutical Co Ltd
SJT Molecular Research SL
Takeda Pharmaceutical Co Ltd
Toray Industries Inc
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
WhanIn Pharmaceutical Co Ltd
XL-protein GmbH
Yuhan Corp
Yuyu Pharma Inc
Zafgen Inc
Zealand Pharma AS
2
Introduction 8
Obesity - Overview 9
Obesity - Therapeutics Development 10
Obesity - Therapeutics Assessment 38
Obesity - Companies Involved in Therapeutics Development 56
Obesity - Drug Profiles 98
Obesity - Dormant Projects 465
Obesity - Discontinued Products 485
Obesity - Product Development Milestones 489
Appendix 499List of Tables
Number of Products under Development for Obesity, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Obesity - Pipeline by Abeome Corp, H1 2018
Obesity - Pipeline by Adocia SAS, H1 2018
Obesity - Pipeline by Aegis Therapeutics LLC, H1 2018
Obesity - Pipeline by Amgen Inc, H1 2018
Obesity - Pipeline by Antag Therapeutics ApS, H1 2018
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018
Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018
Obesity - Pipeline by AstraZeneca Plc, H1 2018
Obesity - Pipeline by Athersys Inc, H1 2018
Obesity - Pipeline by Auris Medical Holding AG, H1 2018
Obesity - Pipeline by Bial - Portela & Ca SA, H1 2018
Obesity - Pipeline by Biophytis SA, H1 2018
Obesity - Pipeline by BioRestorative Therapies Inc, H1 2018
Obesity - Pipeline by Biozeus, H1 2018
Obesity - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Obesity - Pipeline by Braasch Biotech LLC, H1 2018
Obesity - Pipeline by C3J Therapeutics Inc, H1 2018
Obesity - Pipeline by Callitas Therapeutics Inc, H1 2018
Obesity - Pipeline by Carmot Therapeutics Inc, H1 2018
Obesity - Pipeline by Celon Pharma SA, H1 2018
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Obesity - Pipeline by CohBar Inc, H1 2018
Obesity - Pipeline by CoMentis Inc, H1 2018
Obesity - Pipeline by Corcept Therapeutics Inc, H1 2018
Obesity - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Obesity - Pipeline by DiscoveryBiomed Inc, H1 2018
Obesity - Pipeline by Eisai Co Ltd, H1 2018
Obesity - Pipeline by Eli Lilly and Co, H1 2018
Obesity - Pipeline by Eternygen GmbH, H1 2018
Obesity - Pipeline by Evotec AG, H1 2018
Obesity - Pipeline by FibroGen Inc, H1 2018
Obesity - Pipeline by Genmedica Therapeutics SL, H1 2018
Obesity - Pipeline by Gila Therapeutics Inc, H1 2018
Obesity - Pipeline by Gilead Sciences Inc, H1 2018
Obesity - Pipeline by GlaxoSmithKline Plc, H1 2018
Obesity - Pipeline by Glucox Biotech AB, H1 2018
Obesity - Pipeline by HanAll Biopharma Co Ltd, H1 2018
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018
Obesity - Pipeline by Immungenetics AG, H1 2018
Obesity - Pipeline by Intarcia Therapeutics Inc, H1 2018
Obesity - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Obesity - Pipeline by Johnson & Johnson, H1 2018
Obesity - Pipeline by Juno Therapeutics Inc, H1 2018
Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Obesity - Pipeline by Lead Discovery Center GmbH, H1 2018
Obesity - Pipeline by Leading BioSciences Inc, H1 2018
Obesity - Pipeline by Magnus Life Ltd, H1 2018
Obesity - Pipeline by MedImmune LLC, H1 2018
Obesity - Pipeline by Merck & Co Inc, H1 2018
Obesity - Pipeline by Naia Ltd, H1 2018List of Figures
Number of Products under Development for Obesity, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Research Methodology
The research study released with title "Obesity - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Obesity Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Obesity Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Obesity Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Obesity Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Obesity - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
